

SCIENTIFIC

The Bureau has an active, on-going scientific research program for the purpose of obtaining better knowledge of dangerous drugs, their chemical structure, and their effect upon humans. Too little is known about the physiological and psychological impact of these highly potent chemicals. In addition, the sociological problems of drug abuse are also an important area of concern. BDAC serves as the catalyst by contracting for scientific research in these areas and by evaluating research results for maximum utilization in the Bureau's education and enforcement programs. Thirteen such contracts have been let to date.

In addition, the Division of Drug Studies and Statistics has the responsibility of authorizing and providing samples of LSD—and other hallucinogens—to State and local crime laboratories upon their request in order to be used as standards in their analytical procedures. The supply of LSD comes from the National Institute of Mental Health. Since the inception of this program, 293 samples of LSD have been forwarded to police crime laboratories.

A thorough knowledge of these dangerous drugs and what they do, coupled with an understanding of the drug abuser and why he abuses drugs, is essential to BDAC's mission.

We have an Advisory Committee on Stimulant and Depressant Drugs composed of eight nationally known scientists who report administratively to me. This Committee studies and advises us on any drug before it is placed under control. The Committee and its functions will be transferred to the Department of Justice with this Bureau.

In order for the Committee to consider a drug for control, a large amount of information must be gathered. One of the sources of such information, especially for stimulants and depressants, is the Investigational New Drug Forms (IND's) and the New Drug Applications (NDA's) which are submitted by the pharmaceutical industry to the Bureau of Medicine of FDA.

In order for the Bureau to conduct its day-to-day responsibilities and programs, it calls on the services and expertise of various members of the National Institute of Mental Health, as well as members of other Bureaus of the Food and Drug Administration. Such contacts are necessary to obtain information on research projects, educational programs and data on the effects of various drugs. The Director of the Division of Drug Studies and Statistics of the Bureau has a joint appointment in the National Institute of Mental Health. This arrangement will continue between the Department of Justice and the NIMH.

This exchange of information with the National Institute of Mental Health and the Food and Drug Administration will be continued so that the Bureau can continue to receive this information as it is needed.

In addition, the Bureau has a cooperative agreement with officials at the Aeromedical Research Laboratory at Holloman Air Force Base, N. Mex., the laboratories and facilities of which are used to examine drug questions of interest to the Air Force and the Bureau. Two staff members of the Bureau are stationed at Holloman. They are concerned with developing screening techniques for stimulants and how one can predict potential for abuse. Arrangements will be made with the Air